Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549092 · ClinicalTrials.gov registry record · Phase 3
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
A Phase 3 study of Advanced Parkinson's Disease, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT02549092 is a Phase 3 study of Advanced Parkinson's Disease that has completed, run by AbbVie. The registered enrollment target is 89 participants, below the 105-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02549092, a Phase 3 study of Advanced Parkinson's Disease, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
Conditions Studied
Interventions
- DRUG Optimized Medical Treatment
- DRUG Levodopa-Carbidopa Intestinal Gel
- DEVICE Nasojejunal (NJ) tube
- DEVICE Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Study Locations (20)
Florida
- Boca Raton Regional Hospital /ID# 200056 - Boca Raton
- University of Florida Neurolog /ID# 168699 - Jacksonville
- Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085 - Port Charlotte
Other
- Central Hospital Bremerhaven /ID# 136573 - Bremerhaven
- Mediterraneo Hospital /ID# 208042 - Glyfada
- Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789 - Bologna
Victoria
- Royal Melbourne Hospital /ID# 136780 - Parkville
- Goulburn Valley Hospital /ID# 164202 - Shepparton
Ontario
- The Ottawa Hospital /ID# 139341 - Ottawa
- Toronto Western Hospital /ID# 136585 - Toronto
California
- Parkinson's and Movement /ID# 161596 - Fountain Valley
Illinois
- Rush University Medical Center /ID# 168088 - Chicago
Missouri
- St. Luke's Health System /ID# 168706 - Kansas City
Texas
- Central Texas Neurology Consul /ID# 168087 - Round Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2015-10-26 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549092
The ClinicalTrials.gov registry entry for NCT02549092 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (15% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Parkinson's Disease appearing as the primary indexed condition, and to 4 interventions - of which Optimized Medical Treatment is the first listed.
NCT02549092 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Other, Victoria.
Frequently Asked Questions
What is clinical trial NCT02549092 about?
NCT02549092 is a clinical study titled "A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)". The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
What is the current status of trial NCT02549092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2015-10-26. Estimated completion is 2022-11-18.
What conditions does trial NCT02549092 study?
This clinical trial studies the following conditions: Advanced Parkinson's Disease.
What interventions are being tested in trial NCT02549092?
The interventions under investigation include: Optimized Medical Treatment (DRUG), Levodopa-Carbidopa Intestinal Gel (DRUG), Nasojejunal (NJ) tube (DEVICE), Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube (DEVICE).
Who is sponsoring clinical trial NCT02549092?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549092 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
COMPLETED · Phase 3
-
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
RECRUITING · Phase 1
-
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.